论文部分内容阅读
目的观察亚甲基四氢叶酸还原酶(MTHFR)C667T基因多态性与5-氟尿嘧啶(5-FU)为基础的化疗方案治疗晚期胃癌的疗效间的关系。方法收集经病理学确诊的晚期胃癌59例。所有病例化疗前抽取外周静脉血,提取DNA,用连接酶检测反应技术(LDR)检测研究对象的MTHFR基因型。所有患者经5-FU为基础的联合化疗方案化疗。结果 59例晚期胃癌患者中,21例(35.59%)为MTHFRC/C基因型,22例(37.29%)为MTHFRC/T基因型,16例(27.12%)为MTHFRT/T基因型。其中,4例CR,14例PR,19例SD,22例PD,总有效率为30.51%(18/59)。MTHFRT/T基因型患者的化疗有效率(68.75%)明显高于C/T基因型患者(18.18%)(P<0.01),也明显高于C/C基因型(14.29%)(P<0.01)。结论 MTHFR基因型对预测以5-FU为基础化疗方案治疗晚期胃癌的疗效具有较好的临床意义。
Objective To investigate the relationship between the efficacy of methylenetetrahydrofolate reductase (MTHFR) C667T gene polymorphism and 5-fluorouracil (5-FU) -based chemotherapy in the treatment of advanced gastric cancer. Methods Fifty-nine patients with pathologically diagnosed advanced gastric cancer were collected. In all cases, peripheral venous blood was drawn before chemotherapy, DNA was extracted, and MTHFR genotypes were examined by ligase detection reaction (LDR). All patients underwent 5-FU-based chemotherapy with chemotherapy. Results Among the 59 patients with advanced gastric cancer, 21 (35.59%) were MTHFRC / C genotypes, 22 (37.29%) were MTHFRC / T genotypes and 16 (27.12%) were MTHFRT / T genotypes. Among them, 4 cases of CR, 14 cases of PR, 19 cases of SD, 22 cases of PD, the total effective rate was 30.51% (18/59). The effective rate of chemotherapy (68.75%) in patients with MTHFRT / T genotype was significantly higher than that in C / T genotype (18.18%) (P <0.01) and significantly higher than that of C / C genotype (14.29%) ). Conclusion MTHFR genotype has a good clinical value in predicting the efficacy of 5-FU-based chemotherapy in the treatment of advanced gastric cancer.